When to Prescribe Atorvastatin
Atorvastatin should be prescribed for all adults with established atherosclerotic cardiovascular disease (ASCVD) using high-intensity therapy (40-80 mg daily), and for primary prevention in adults aged 40-75 years with diabetes, LDL-C ≥190 mg/dL, or 10-year ASCVD risk ≥7.5% with additional risk factors. 1, 2, 3
Secondary Prevention (Established ASCVD)
High-intensity atorvastatin (40-80 mg daily) is mandatory for all patients with established ASCVD, including those with prior myocardial infarction, acute coronary syndrome, stroke/TIA (non-cardioembolic), peripheral arterial disease, or prior coronary revascularization. 1, 4, 3
- Target LDL-C <55 mg/dL (<1.4 mmol/L) with ≥50% reduction from baseline 4, 3
- For patients with recurrent atherosclerotic events within 2 years while on maximum statin therapy, consider an even lower target of <40 mg/dL (<1.0 mmol/L) 3
- Initiate atorvastatin 80 mg immediately in acute coronary syndrome patients, regardless of baseline LDL-C levels 4
- For ischemic stroke/TIA patients without cardioembolic mechanism and LDL-C >100 mg/dL, prescribe atorvastatin 80 mg to reduce stroke recurrence 5, 6
Important caveat: In patients with recent hemorrhagic stroke, atorvastatin 80 mg carries increased risk of recurrent hemorrhagic stroke (2.3% vs 1.4% with placebo), though non-fatal events drive this difference 7
Primary Prevention
Diabetes Mellitus
All adults aged 40-75 years with diabetes require statin therapy, with intensity based on ASCVD risk stratification: 1, 8, 9
- High-intensity atorvastatin (40-80 mg) for those with multiple ASCVD risk factors or 10-year risk ≥20%, targeting LDL-C <70 mg/dL 1
- Moderate-intensity atorvastatin (10-20 mg) for those aged 40-75 without additional risk factors 1, 8
- For ages 20-39 with additional ASCVD risk factors, consider moderate-intensity therapy 1
- For ages >75 already on therapy, continue treatment; for new initiations, discuss risks/benefits before starting moderate-intensity therapy 1
Type 1 diabetes with microalbuminuria/renal disease requires statin therapy (≥50% LDL-C reduction) regardless of baseline LDL-C 4
Severe Hypercholesterolemia
Prescribe maximum tolerated atorvastatin (up to 80 mg) for LDL-C ≥190 mg/dL (≥4.9 mmol/L) in adults aged 20-75 years, often requiring combination with ezetimibe 2, 9
- Suspect familial hypercholesterolemia in adults with LDL-C >190 mg/dL, especially with premature CHD family history or tendon xanthomas 4
- For heterozygous familial hypercholesterolemia, use high-intensity atorvastatin often combined with ezetimibe 4
Risk-Based Primary Prevention (Ages 40-75)
Calculate 10-year ASCVD risk using Pooled Cohort Equations to guide therapy: 2, 9
High Risk (≥20% 10-year ASCVD risk):
Intermediate Risk (7.5% to <20% 10-year ASCVD risk):
- Moderate-intensity atorvastatin (10-20 mg) is recommended after risk discussion, targeting ≥30% LDL-C reduction 2, 9
- Consider coronary artery calcium (CAC) scoring if decision remains uncertain: 2, 9
- CAC = 0: Withhold statin, reassess in 5-10 years (unless diabetes, smoking, or premature CHD family history present)
- CAC 1-99: Initiate statin if age ≥55 years
- CAC ≥100 or ≥75th percentile: Initiate statin therapy
- Risk-enhancing factors favoring statin initiation include: family history of premature ASCVD, chronic kidney disease (eGFR 15-59), metabolic syndrome, chronic inflammatory conditions, premature menopause, South Asian ancestry, persistently elevated LDL-C ≥160 mg/dL, or elevated high-sensitivity CRP (≥2.0 mg/L) 2, 6, 9
Borderline Risk (5% to <7.5% 10-year ASCVD risk):
- Consider moderate-intensity atorvastatin (10-20 mg) only if multiple risk-enhancing factors present after shared decision-making 2, 9
Special Populations
Chronic Kidney Disease (Stage 3-5, non-dialysis):
- Prescribe atorvastatin or atorvastatin/ezetimibe combination; these patients are high or very high cardiovascular risk 4
- Do not initiate statins in dialysis-dependent patients without established ASCVD 4
Peripheral Arterial Disease:
- Treat as very high-risk; prescribe high-intensity atorvastatin targeting LDL-C <55 mg/dL 4
Older Adults (>75 years):
- Continue atorvastatin if already prescribed 1
- For new initiations, discuss potential benefits/risks before starting moderate-intensity therapy 1
Dosing Strategy
Atorvastatin intensity classification: 1, 8, 7
- High-intensity: 40-80 mg daily (achieves ≥50% LDL-C reduction)
- Moderate-intensity: 10-20 mg daily (achieves 30-49% LDL-C reduction)
Starting doses: 7
- Standard starting dose: 10-20 mg daily
- For patients requiring >45% LDL-C reduction: Start 40 mg daily
- Take once daily with or without food 7
Monitoring and Escalation
- Assess LDL-C at 4-6 weeks after initiation or dose change 1, 10, 3
- If target not achieved on maximum tolerated atorvastatin, add ezetimibe 1, 10, 3
- If still not at target after 4-6 weeks on atorvastatin plus ezetimibe, add PCSK9 inhibitor 1, 10, 3
- For statin-intolerant patients, use maximum tolerated dose; consider bempedoic acid or ezetimibe monotherapy 1, 3
Key Contraindications and Precautions
Do not prescribe atorvastatin in: 7
- Acute liver failure or decompensated cirrhosis
- Pregnancy or planned pregnancy
- Hypersensitivity to atorvastatin
Exercise caution and monitor closely for myopathy/rhabdomyolysis with: 7
- Age ≥65 years
- Uncontrolled hypothyroidism
- Renal impairment
- Concomitant use of cyclosporine, gemfibrozil, tipranavir plus ritonavir, or glecaprevir plus pibrentasvir (avoid combination)
- Large quantities of grapefruit juice (>1.2 liters daily)
Monitor liver enzymes before initiation and when clinically indicated; discontinue if serious hepatic injury develops 7